Description
This issue of Cardiology Clinics, edited by Dr. Stephen Nicholls, focuses on Lipidology. Topics include, but are not limited to: Impact of lipoproteins on atherobiology; Lessons from genomic studies; Lipids and lipoproteins in risk prediction; Optimizing statins and ezetimibe in guideline focused management; Statin intolerance; Lipid lowering agents and diabetes risk; PCSK9 inhibitors; Bempedoic Acid; Triglyceride rich lipoproteins; Omega 3 Fatty Acids; Lipoprotein; CETP inhibitors; HDL infusions; and Targeting HDL functionality.
Table of Contents
Lipidology – Table of ContentsPreface: LipidologyImpact of Lipoproteins on Atherobiology: Emerging InsightsCausal Effect of Lipids and Lipoproteins on Atherosclerosis: Lessons from Genomic StudiesLipids and Lipoproteins in Risk PredictionOptimizing Statins and Ezetimibe in Guideline-Focused ManagementStatin Intolerance: Some Practical HintsTreating Dyslipidemia in Type 2Proprotein Convertase Subtilisin Kexin 9 InhibitorsBempedoic Acid (ETC-1002): A Current ReviewTriglyceride-Rich LipoproteinsEvolution of Omega-3 Fatty Acid Therapy and Current and Future Role in the Management of DyslipidemiaIs Lipoprotein(a) Ready for Prime-Time Use in the Clinic?Cholesteryl Ester Transfer Protein Inhibitors as Agents to Reduce Coronary Heart Disease RiskHigh-Density Lipoprotein InfusionsHigh-Density Lipoproteins: Effects on Vascular Function and Role in the Immune ResponseIntravascular Ultrasound Studies of Plaque Progression and Regression: Impact of Lipid-Modifying Therapies
